Oxford Immunotec Global (NASDAQ:OXFD) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

OXFD has been the topic of a number of other research reports. Piper Jaffray Companies dropped their target price on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 31st. Zacks Investment Research lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Wednesday, August 30th. Robert W. Baird reissued a “buy” rating and issued a $20.00 target price on shares of Oxford Immunotec Global in a research report on Wednesday, November 1st. BTIG Research set a $21.00 target price on Oxford Immunotec Global and gave the company a “buy” rating in a research report on Tuesday, October 31st. Finally, ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $19.75.

Shares of Oxford Immunotec Global (OXFD) opened at $13.63 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global has a 1 year low of $12.19 and a 1 year high of $19.51.

In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the sale, the director now owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. 8.11% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of OXFD. Perceptive Advisors LLC increased its position in shares of Oxford Immunotec Global by 955.1% during the 3rd quarter. Perceptive Advisors LLC now owns 465,356 shares of the company’s stock worth $7,818,000 after purchasing an additional 421,250 shares during the last quarter. Alyeska Investment Group L.P. increased its position in shares of Oxford Immunotec Global by 44.0% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock worth $22,773,000 after purchasing an additional 413,904 shares during the last quarter. RTW Investments LP increased its position in shares of Oxford Immunotec Global by 21.9% during the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock worth $17,344,000 after purchasing an additional 185,453 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Oxford Immunotec Global during the 3rd quarter worth approximately $2,726,000. Finally, Columbus Circle Investors acquired a new position in shares of Oxford Immunotec Global during the 3rd quarter worth approximately $2,640,000. 89.35% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/09/bidaskclub-lowers-oxford-immunotec-global-oxfd-to-sell.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.